ArticleEye (London, England)2026
AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate early morphological changes following intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration (nAMD) using artificial intelligence (AI)-assisted optical coherence tomography (OCT) segmentation.
methodsThirty eyes with treatment-naïve subfoveal nAMD received three monthly aflibercept 8 mg injections. OCT scans were obtained at baseline and days 1, 7, 14, 30, 60, and 90. AI-based segmentation software (Fluid Monitor, RetInSight GmbH) quantified intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) volumes in the central 6-mm area. Morphologic changes were correlated with best-corrected visual acuity (BCVA).
resultsIRF, SRF, and PED showed distinct reduction patterns. In eyes with IRF (n = 22), mean volume decreased by 65% at day 1, 94% at day 14, and 96% at day 90 (p < 0.05). Among eyes with SRF (n = 28), SRF volume decreased by 18%, 84%, and 99% at days 1, 14, and 90, respectively (p ≤ 0.002). PED volume declined more gradually among affected eyes (n = 23), with mean reductions of 7% at day 1, 34% by day 14, and 53% by day 90 (p ≤ 0.023). BCVA improved from 51.8 ± 14.4 to 62.6 ± 14.4 ETDRS letters by day 90 (mean gain + 10.8; p < 0.001). Multivariate regression identified a significant association between IRF reduction at day 14 and BCVA gain at day 90 (β = -0.018, p = 0.036).
conclusionsAflibercept 8 mg induced rapid, compartment-specific morphologic responses in treatment-naïve nAMD, with early IRF resolution and significant BCVA improvement. AI-assisted analysis provided detailed pharmacodynamic insights and may support individualised treatment strategies during the loading phase.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.